^
Association details:
Biomarker:No biomarker
Cancer:Follicular Lymphoma
Drug:Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
ALIQOPA is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies…
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Follicular Lymphoma: Second-line and Subsequent therapy…Other recommended regimens…PI3K inhibitors (relapsed/refractory after 2 prior therapies)…Copanlisib